Drug Trial Radar · NCT07030517
A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple Myeloma
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
75
Actual
Start
May 22, 2025
Primary completion
Feb 12, 2027
Study completion Feb 14, 2027
Sponsor
- Lead sponsor
- Johnson & Johnson Private LimitedJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Jun 22, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety of teclistamab in routine clinical practice when given as monotherapy in Indian participants with relapsed and refractory multiple myeloma (RRMM) (that is, a blood cancer that comes back after treatment or does not respond to treatment) who have previously received at least 3 prior lines of therapy including an immunomodulatory agent, a proteasome inhibitor and an anti-cluster of differentiation (CD)38 antibody (is a protein that fights infection) and whose disease have progressed on the last therapy.
Conditions
- Multiple Myeloma
Interventions
TeclistamabDrug
Teclistamab will be administered subcutaneously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Treatment-Emergent Adverse Events (TEAE)sTime frame: Up to approximately 2 years 1 month
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
M S Ramaiah Medical College and Hospital
Bangalore, India
St. Johns Medical College And Hospital
Bengaluru, India
Post Graduate Institute of Medical Education And Research PGIMER
Chandigarh, India
Bhagwan Mahaveer Cancer Hospital & Research Centre
Jaipur, India
Tata Medical Center
Kolkata, India
Tata Memorial Hospital
Mumbai, India
KIMS-Kingsway Hospitals
Nagpur, India
All India Institute of Medical Sciences
New Delhi, India
Rajiv Gandhi Cancer Institute & Research Centre
New Delhi, India
Jawaharlal Institute of Postgraduate Medical Education and Research
Puducherry, India
Christian Medical College
Ratnagiri Kilminnal, India
Regional Cancer Centre
Thiruvananthapuram, India
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.